Related Experiment Video
Updated: May 18, 2026
06:10
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Current status of mechanical circulatory support: a systematic review
Kyriakos Spiliopoulos1, Gregory Giamouzis, George Karayannis
1Department of Thoracic and Cardiovascular Surgery, Larissa University Hospital, P.O. Box 1425, 411 10 Larissa, Greece.
Cardiology Research and Practice
|September 13, 2012
Summary
Mechanical circulatory support devices (MCSDs) are increasingly vital for managing heart failure due to donor organ shortages. This review details the current status of MCSDs in advanced heart failure treatment.
Area of Science:
- Cardiology
- Medical Devices
- Public Health
Background:
- Heart failure is a significant public health issue with high mortality, despite optimal medical treatment.
- Therapeutic strategies have improved, but the prevalence of heart failure continues to rise dramatically.
- Heart transplantation is the gold standard, but limited donor organs restrict its widespread use.
Purpose of the Study:
- To outline the current status of mechanical circulatory support devices (MCSDs) in managing end-stage heart failure.
- To highlight the growing importance of MCSDs as a therapeutic option.
- To provide an overview of advancements and applications in mechanical circulatory support.
Main Methods:
- Literature review of current research and clinical practices regarding MCSDs.
- Analysis of the role of MCSDs in the context of heart transplantation limitations.
- Synthesis of information on the evolution and established use of MCSDs.
Main Results:
- Mechanical circulatory support devices (MCSDs) have become a well-established management strategy for heart failure.
- The utilization of MCSDs has increased significantly due to the shortage of donor organs.
- MCSDs offer a viable alternative for patients with end-stage heart failure.
Conclusions:
- Mechanical circulatory support devices (MCSDs) play a crucial role in addressing the growing burden of heart failure.
- The development and application of MCSDs are essential for improving outcomes in patients ineligible for transplantation.
- Continued advancements in MCSDs are critical for the future of heart failure management.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.